WO2001046388A3 - Krankhaft veränderte herzmuskelzelle, ihre herstellung und verwendung - Google Patents

Krankhaft veränderte herzmuskelzelle, ihre herstellung und verwendung Download PDF

Info

Publication number
WO2001046388A3
WO2001046388A3 PCT/EP2000/013101 EP0013101W WO0146388A3 WO 2001046388 A3 WO2001046388 A3 WO 2001046388A3 EP 0013101 W EP0013101 W EP 0013101W WO 0146388 A3 WO0146388 A3 WO 0146388A3
Authority
WO
WIPO (PCT)
Prior art keywords
myocardial cell
pathologically modified
production
modified myocardial
pathologically
Prior art date
Application number
PCT/EP2000/013101
Other languages
English (en)
French (fr)
Other versions
WO2001046388A2 (de
Inventor
Volker Roenicke
Barbara Nave
Thomas Henkel
Original Assignee
Medigene Ag
Volker Roenicke
Barbara Nave
Thomas Henkel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene Ag, Volker Roenicke, Barbara Nave, Thomas Henkel filed Critical Medigene Ag
Priority to AU26757/01A priority Critical patent/AU2675701A/en
Priority to JP2001546886A priority patent/JP2004500065A/ja
Priority to EP00990011A priority patent/EP1244772A2/de
Priority to CA002395228A priority patent/CA2395228A1/en
Priority to US10/168,235 priority patent/US20030170890A1/en
Publication of WO2001046388A2 publication Critical patent/WO2001046388A2/de
Publication of WO2001046388A3 publication Critical patent/WO2001046388A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/365—Endothelin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Krankhaft veränderte Herzmuskelzelle, herstellbar aus gesundem Herzgewebe durch Bereitstellen oder Isolieren von mindestens einer gesunden Herzmuskelzelle, Stimulieren der isolierten Herzmuskelzelle durch geeignete Hormone, Hormonanaloga und/oder Zytokine; Nachweis der mindestens einen krankhaft veränderten Herzmuskelzelle durch Bestimmen der Lokalisation mindestens eines Signalmoleküls sowie Verfahren zu ihrer Herstellung und ihre Verwendung einschließlich eines Verfahrens zum Nachweis oder zur Identifizierung herzaktiver Substanzen.
PCT/EP2000/013101 1999-12-22 2000-12-21 Krankhaft veränderte herzmuskelzelle, ihre herstellung und verwendung WO2001046388A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU26757/01A AU2675701A (en) 1999-12-22 2000-12-21 Pathologically modified myocardial cell, production and use thereof
JP2001546886A JP2004500065A (ja) 1999-12-22 2000-12-21 病的に修飾された心筋細胞、その産生と使用
EP00990011A EP1244772A2 (de) 1999-12-22 2000-12-21 Krankhaft veränderte herzmuskelzelle, ihre herstellung und verwendung
CA002395228A CA2395228A1 (en) 1999-12-22 2000-12-21 Pathologically modified myocardial cell, production and use thereof
US10/168,235 US20030170890A1 (en) 1999-12-22 2000-12-21 Pathologically modified myocardial cell, production and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19962154A DE19962154A1 (de) 1999-12-22 1999-12-22 Krankhaft veränderte Herzmuskelzelle, ihre Herstellung und Verwendung
DE19962154.3 1999-12-22

Publications (2)

Publication Number Publication Date
WO2001046388A2 WO2001046388A2 (de) 2001-06-28
WO2001046388A3 true WO2001046388A3 (de) 2002-02-07

Family

ID=7933902

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/013101 WO2001046388A2 (de) 1999-12-22 2000-12-21 Krankhaft veränderte herzmuskelzelle, ihre herstellung und verwendung

Country Status (7)

Country Link
US (1) US20030170890A1 (de)
EP (1) EP1244772A2 (de)
JP (1) JP2004500065A (de)
AU (1) AU2675701A (de)
CA (1) CA2395228A1 (de)
DE (1) DE19962154A1 (de)
WO (1) WO2001046388A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003025205A2 (en) * 2001-09-19 2003-03-27 Medigene Ag Extracellular regulated kinase 2 (erk2)
US9945840B2 (en) 2004-04-07 2018-04-17 Axiogenesis Ag Non-invasive, in vitro functional tissue assay systems
CA2565858C (en) * 2004-05-11 2021-06-22 Axiogenesis Ag Assay for drug discovery based on in vitro differentiated cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056907A1 (de) * 1997-06-13 1998-12-17 Medigene Aktiengesellschaft Herz- und skelettmuskel-spezifische nukleinsäure, ihre herstellung und verwendung

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5573762A (en) * 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056907A1 (de) * 1997-06-13 1998-12-17 Medigene Aktiengesellschaft Herz- und skelettmuskel-spezifische nukleinsäure, ihre herstellung und verwendung

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
EBLE DIANE M ET AL: "Contractile activity is required for sarcomeric assembly in phenylephrine-induced cardiac myocyte hypertrophy.", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 274, no. 5 PART 1, May 1998 (1998-05-01), pages C1226 - C1237, XP001008250, ISSN: 0002-9513 *
GENG YONG-JIAN ET AL: "Apoptosis of cardiac myocytes in Gsalpha transgenic mice.", CIRCULATION RESEARCH, vol. 84, no. 1, January 1999 (1999-01-01), pages 34 - 42, XP001007327, ISSN: 0009-7330 *
HIROTA HISAO ET AL: "Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 92, no. 11, 1995, 1995, pages 4862 - 4866, XP002174424, ISSN: 0027-8424 *
MORISCO CARMINE ET AL: "Gs-coupled beta1 adrenergic receptors stimulate hypertrophy in cultured neonatal rat cardiac myocytes.", CIRCULATION, vol. 110, no. 18 SUPPL., 2 November 1999 (1999-11-02), 72nd Scientific Sessions of the American Heart Association;Atlanta, Georgia, USA; November 7-10, 1999, pages I.487, XP001008359, ISSN: 0009-7322 *
VIDAL MARC UND ENDOH HIDEKI: "Prospects for drug screening using the reverse two-hybrid system", TIBTECH, vol. 17, September 1999 (1999-09-01), pages 374 - 381, XP001008340 *
WOLLERT KAI C ET AL: "Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy: Assembly of sarcomeric units in series VIA gp130/leukemia inhibitory factor receptor-dependent pathways.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 16, 1996, pages 9535 - 9545, XP001008822, ISSN: 0021-9258 *
YAMAZAKI TSUTOMU ET AL: "Role of the renin-angiotensin system in cardiac hypertrophy.", AMERICAN JOURNAL OF CARDIOLOGY, vol. 83, no. 12A, 17 June 1999 (1999-06-17), pages 53H - 57H, XP001007329, ISSN: 0002-9149 *
ZECHNER DIETMAR ET AL: "A role for the p38 mitogen-activated protein kinase pathway in myocardial cell growth, sarcomeric organization, and cardiac-specific gene expression.", JOURNAL OF CELL BIOLOGY, vol. 139, no. 1, 1997, pages 115 - 127, XP001008249, ISSN: 0021-9525 *

Also Published As

Publication number Publication date
DE19962154A1 (de) 2001-07-12
AU2675701A (en) 2001-07-03
CA2395228A1 (en) 2001-06-28
EP1244772A2 (de) 2002-10-02
US20030170890A1 (en) 2003-09-11
WO2001046388A2 (de) 2001-06-28
JP2004500065A (ja) 2004-01-08

Similar Documents

Publication Publication Date Title
CA2298018A1 (en) Methods and compositions for inhibiting angiogenesis
WO2006015086A3 (en) Methods of affecting hypothalamic-related conditions
WO2002007707A3 (en) Linkage of agents using microparticles
WO2002031507A3 (en) Non-invasive enzyme screen for tissue remodelling-associated conditions
GB0306629D0 (en) Monitoring electrical muscular activity
WO2003053510A3 (en) Apparatus and method for multi-site anti-tachycardia pacing
MXPA02006145A (es) Metodo para el aislamiento de arn de especimenes de tejido incluido en parafina fijo en formalina.
EP0301639A3 (de) Analoge von das Bradykinin verstärkendem Peptid BPP 5a und Methode zu deren Herstellung
AU2681497A (en) Novel agouti-related gene
WO2000066528A3 (en) Quinones for treatment of diseases
WO2001045678A3 (de) Arzneimittel, verfahren zu dessen herstellung und dessen verwendung
MXPA02009275A (es) Metodo para preparar dispersiones de alta presion/alto esfuerzo cortante que contienen ingredientes fisiologicamente activos.
DE69919787D1 (de) Multi-Ort, parameter- gesteuerter, implantierbarer Herzschrittmacher / Defribrillator
AU7852600A (en) Iontophoretic delivery to heart tissue
WO2001020031A3 (en) Polymorphisms in a klotho gene
WO2001046388A3 (de) Krankhaft veränderte herzmuskelzelle, ihre herstellung und verwendung
WO2005018682A3 (en) Somatostatin analogs with inhibitory activity to growth hormone release
AU6539000A (en) Composition and method for treating disease by increasing activated alpha2 macroglobulin in the blood and extravascular tissue
IE781840L (en) Detecting cancerigenic and anticancerous substances
AU5780398A (en) Pharmaceutical composition for treatment of heart disease based on cardiac hypertrophy
WO2001072328A3 (en) Methods of treating diseases with activated protein c
AU1499101A (en) Leather tanning
ATE337020T1 (de) Fettsaure analoge zur diagnose von kranzarterie erkrankungen
WO2001032693A3 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
WO1999021538A3 (de) Verwendung von glykosaminoglykanen zur herstellung von pharmazeutischen zubereitungen zur behandlung von mit diabetes assoziierten augenkrankheiten

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

WWE Wipo information: entry into national phase

Ref document number: 2000990011

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2395228

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 26757/01

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 546886

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000990011

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10168235

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000990011

Country of ref document: EP